Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05312567
Other study ID # 2021-FERV
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 24, 2021
Est. completion date July 31, 2023

Study information

Verified date October 2023
Source Fervent Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase II proof of concept study is designed to assess the safety and efficacy of FP-101 (60mg b.i.d.), an extended-release oral tablet product, compared to a matching placebo in the treatment of moderate-to-severe hot flashes in peri- and post-menopausal women over a period of 1-week.


Description:

This randomized, double-blind, parallel-group, placebo-controlled, clinical trial is designed to compare patient-reported changes in Vasomotor Symptoms (VMS) for FP-101 vs. placebo in peri- and post-menopausal women. The study will be run as a fully decentralized clinical trial (DCT), by use of components such as electronic Consent (eConsent), mobile/tele health visits, electronic Patient Reported Outcomes (ePROs), and direct-to-participant shipping of the (investigational medicinal product (IMP). The DCT approach to this study will rely on a digital platform through which subjects can consent, enroll, and interact with the PI and study staff. Proper regulatory framework and technology use will ensure compliance with Good Clinical Practice (GCP), ethics & legal/regulatory requirements. Healthy peri- and post-menopausal women (>45 years of age) suffering from VMS will be recruited if they have >=7- 8 moderate to severe hot flushes per day at baseline. After meeting all eligibility criteria subjects will be enrolled and start a 1-week run-in period to identify/eliminate placebo responders, as well as to exclude subjects who have difficulty completing the eDiary. Any Adverse Events (AEs) during the run-in period will serve as baseline for the safety assessments at the end of the treatment period. Eligible subjects will undergo a tele health baseline visit during which the criteria for inclusion in the treatment period will be confirmed. Over a 1-week treatment period, subjects will complete a daily electronic Diary (eDiary) to record any AEs and the frequency and severity of hot flashes during the past 12hr interval. In the morning, subjects will record the number of awakenings during the past night and the number of night sweats. The PI will conduct an end-of-study visit with each of the subjects randomized to the study medications to review safety and efficacy data, complete a Patient Global Improvement Scale, and clarify any open issues with the subjects. ------------------------------


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date July 31, 2023
Est. primary completion date April 5, 2023
Accepts healthy volunteers No
Gender Female
Age group 46 Years and older
Eligibility Inclusion Criteria: - Peri- and Post-Menopausal female subjects (>45 yrs) experiencing a min of 7-8 moderate to severe hot flashes per day - Able/willing to provide informed consent. - Able/willing to complete all study procedures and visits. - Able/willing to not use any over-the-counter (OTC) cough & cold medications that contain the IMP active during the study. Exclusion Criteria: - Subject exhibits positive home pregnancy test at screening or any time during study - Subject currently taking any form of Hormone Therapy (HT), including local estrogen therapies - Subject currently taking tamoxifen, other selective estrogen receptor modulators, or other hormone deprivation therapy. - Subject with history of serotonergic syndrome - Subject is currently taking monoamine oxidase inhibitors (MAOIs) (or for 2 weeks after stopping the MAOI drug), antidepressants, thioridazine, pimozide, cannabidiol, opioids, antipsychotic agents, antiretroviral agents, quinidine, quinine, or other medications for VMS such as BrisdelleĀ® (paroxetine mesylate), clonidine and gabapentin. - Subject is currently taking a dietary/herbal supplement(s) to manage VMS, such as soy isoflavones or black cohosh. - Subject has uncontrolled diabetes, a history of hypertension & is not on a stable dose of antihypertensive medications for at least 30 days prior to screening. - Subject has clinically unstable cardiac disease, including atrial fibrillation, symptomatic brady- or tachy-arrhythmias, congestive heart failure (NYHA class II, III, and IV), or symptomatic atherosclerotic cardiovascular disease (coronary artery disease, carotid artery disease or peripheral artery disease) or history of myocardial infarction or stroke within 2 years of enrolment in the study. - Subject reports medical history suggestive of impaired liver/kidney function or, in the PI's opinion, exhibits liver/kidney function impairment to the extent that the subject should not participate in the study. - Subject has biliary tract disease, adrenal cortical insufficiency, or any other medical condition that, in the PI's opinion (and after discussion with the medical monitor), is considered inadequately treated and precludes entry into the study. - Subject has thyroid disease, unless subject is clinically stable with normal thyroid indices and is on maintenance thyroid medication (e.g., levothyroxine or liothyronine) for =6 months prior to screening. - Subject has a history of, or is currently presenting with, substance use disorder as defined by the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Subject has a history of psychiatric disorders, including a lifetime history of major depressive disorder, bipolar disorder, panic disorder, generalized anxiety, psychotic disorders, suicidality or suicidal ideation, or post-traumatic stress disorder. - Subject is currently participating in another clinical trial - Subjects who were determined to be placebo responders or non-compliant during the 1-week run-in period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FP-101
daily oral tablet administration (b.i.d.)

Locations

Country Name City State
United States Cary Medical Group Cary North Carolina
United States Inpatient Research Clinic Hialeah Florida
United States Torrance Clinical Research Institute Lomita California
United States Long Beach Clinical Trial Services Long Beach California
United States The Angel Medical Research Corporation Miami Lakes Florida
United States Suncoast Clinical Research - Pasco County New Port Richey Florida
United States Coastal Carolina Research Center North Charleston South Carolina
United States Clinical Research of Philadelphia Philadelphia Pennsylvania
United States Raleigh Medical Group Raleigh North Carolina
United States Discovery Clinical Trials - Stone Oak San Antonio Texas
United States ICON Early Phase Services San Antonio Texas
United States Provideré Research Inc. West Covina California

Sponsors (2)

Lead Sponsor Collaborator
Fervent Pharmaceuticals ICON plc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Any Adverse Events and Concomitant Medications Subjects will use daily eDiary to record any AEs and concomitant medications Recorded as needed/every 12 hrs over a 1-week treatment period.
Primary Change in the frequency (average daily number) of moderate-to-severe hot flashes. Subjects use a digital platform to record hot flash frequency in a daily eDiary. Recorded every 12 hrs over a 1-week treatment period.
Secondary Change in the severity (average daily rating) of moderate-to-severe hot flashes. Subjects use digital platform to record hot flash severity (3-point scale) in a daily eDiary. Recorded every 12 hrs over a 1-week treatment period.
Secondary Change in nighttime awakenings (average daily number) with or without night sweats. Subjects use daily eDiary to record nighttime awakenings & night sweats frequency. Recorded every morning over a 1-week treatment period.
Secondary Evaluate the clinical meaningfulness of VMS changes after 1-week of treatment. Completing validated Patient Global Improvement Scale (7-point) with PI. After 1 week of treatment at the end-of-study visit.
See also
  Status Clinical Trial Phase
Completed NCT04553029 - A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
Completed NCT03672513 - Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause N/A
Terminated NCT03642119 - Validation of an Objective Instrument to Measure Hot Flashes During Menopause
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04210583 - RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Completed NCT05617287 - An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause N/A
Recruiting NCT05180266 - Therapeutic Touch and Music in The Menopausal Period N/A
Recruiting NCT04043520 - Bioenergetic Effects of Aging and Menopause (BEAM) Phase 4
Completed NCT03663075 - Effect of Group Education and Individual Counselling on Mental Health and Quality of Life in 45-60 Year Old Women N/A
Completed NCT03363997 - Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days Phase 1
Not yet recruiting NCT04724135 - Assessment of Menopause Related Quality of Life Among Health Professionals in University Hospitals of UMC in Nur-Sultan
Not yet recruiting NCT04728126 - Menopausal Symptoms and Burnout: Comparison of Occupational Health Issue Among Health Professionals in UMC Hospitals
Completed NCT02274571 - Raising Insulin Sensitivity in Post Menopause Early Phase 1
Completed NCT02430987 - Low Sexual Desire and Metabolic Syndrome N/A
Completed NCT02253173 - Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women Phase 3
Completed NCT01757340 - Calorie Restriction With Leucine Supplementation N/A
Recruiting NCT01488903 - A Cohort Research of Genetic Susceptibility for Common Obesity in Women N/A
Terminated NCT01633814 - Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women N/A
Completed NCT00599456 - Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women. N/A